HH-018
/ Huahui Health
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
A tumor microenvironment-targeting CD98-directed ADC confers robust anti-tumor activity in multiple cancers with favorable pharmacokinetics and safety profiles in preclinical models
(AACR 2024)
- "Sesutecan previously demonstrated promising characteristics in preclinical studies with multiple targets and conferred an encouraging benefit:risk profile in the clinic with a FRα-directed ADC (rinatabart sesutecan). In summary, our studies demonstrate that the pH-dependent CD98-directed HH018- sesutecan exerts wide-ranging and potent anti-tumor efficacy, as well as favorable PK and safety profiles in preclinical models. HH018-sesutecan is a promising agent for further development in a broad range of CD98-expressing tumors."
Late-breaking abstract • PK/PD data • Preclinical • Tumor microenvironment • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Hypopharyngeal Cancer • Lymphoma • Oncology • Oral Cancer • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • FOLR1 • SLC3A2 • SLC7A5
1 to 1
Of
1
Go to page
1